Artelo Biosciences to Participate in Two Keynote Panels at 3rd Annual International Cannabinoid Derived Pharmaceutical Summit
LA JOLLA, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer and Andy Yates, PhD, Interim Chief Scientific Officer, will participate in separate keynote panels at the 3rd Annual International Cannabinoid Derived Pharmaceuticals Summit, being held virtually on September 15-17, 2020.
The workshop entitled, “Dealing with Intellectual Property (IP) and Market Exclusivity,” on September 15, 2020 at 12:00 p.m. Eastern Time, will feature Mr. Gorgas sharing insights regarding IP strategies applicable to cannabinoid-based drug development, alternatives to IP protection for securing market exclusivity, and hierarchy and strength of protection offered by various IP methods. In the presentation entitled, “Clinical Trial Design, Endpoints and Regulatory Strategies,” on September 16, 2020 at 2:30 p.m. Eastern Time, Dr. Yates will be dscussing Artelo’s ART27.13 program, a high potency GPCR agonist for anorexia associated with cancer as well as the importance of consultation with regulatory authorities through the progression of clinical development.
The 3rd Annual Cannabinoid Derived Pharmaceutical (CDP) Summit: Pioneering the Research & Development of Pharmaceuticals Containing Cannabinoid APIs
About Artelo Biosciences
Investor Relations Contact: